New Gene Mutations Found for Wilms Tumor
By LabMedica International staff writers Posted on 18 Sep 2014 |
The genetic causes of Wilms tumor, a type of kidney cancer found only in children, has been revealed by whole-exome sequencing identifying missense mutations in the microRNA (miRNA)-processing enzymes.
Wilms tumor or nephroblastoma is the most common childhood genitourinary tract cancer and the third most common pediatric solid tumor and it comprises 95% of all renal cancers and 6% of all cancers diagnosed among children less than 15 years of age.
Scientists the University of Texas Southwestern Medical Center (Dallas, TX, USA) performed exome capture and massively parallel sequencing on a discovery set of 15 pairs of Wilms tumors and matched adjacent normal kidney cortices, and subsequently performed whole-exome sequencing on a validation set of 29 additional Wilms tumors. The team of scientists also performed cell culture and immunoprecipitation, small ribonucleic acid (RNA) sequencing.
.
Small RNAs were isolated from each tumor sample and all samples were analyzed using the RNA 6000 Nano LabChip (Agilent Technologies; Santa Clara, CA, USA) on an Agilent Technologies 2100 Bioanalyzer. Western blotting was performed using monoclonal antibodies and miRNA expression was analyzed in engineered cell lines. Libraries produced were sequenced using the HiSeq 2000 (Illumina; San Diego, CA, USA), producing 100 bp paired-end reads.
Examination of tumor miRNA expression, in vitro processing assays and genomic editing in human cells demonstrated that the gene mutations in endoribonuclease Dicer (DICER1) and ribonuclease 3 (DROSHA) influence miRNA processing through distinct mechanisms.
James F. Amatruda, MD, PhD, a Professor of Pediatrics, Molecular Biology, and Internal Medicine, and senior author of the study said, “The most common, and in some ways the most biologically interesting, mutations were found in genes called DROSHA and DICER1. We found that these mutations affected the cell's production of microRNAs, which are tiny RNA molecules that play big roles in controlling the growth of cells, and the primary effect was on a family of microRNAs called let-7. Let-7 is an important microRNA that slows cell growth and in Wilms tumors in which DROSHA or DICER1 were mutated, let-7 RNA is missing, which causes the cells to grow abnormally fast.” The study was published on September 5, 2014, in the journal Nature Communications.
Related Links:
University of Texas Southwestern Medical Center
Agilent Technologies
Illumina
Wilms tumor or nephroblastoma is the most common childhood genitourinary tract cancer and the third most common pediatric solid tumor and it comprises 95% of all renal cancers and 6% of all cancers diagnosed among children less than 15 years of age.
Scientists the University of Texas Southwestern Medical Center (Dallas, TX, USA) performed exome capture and massively parallel sequencing on a discovery set of 15 pairs of Wilms tumors and matched adjacent normal kidney cortices, and subsequently performed whole-exome sequencing on a validation set of 29 additional Wilms tumors. The team of scientists also performed cell culture and immunoprecipitation, small ribonucleic acid (RNA) sequencing.
.
Small RNAs were isolated from each tumor sample and all samples were analyzed using the RNA 6000 Nano LabChip (Agilent Technologies; Santa Clara, CA, USA) on an Agilent Technologies 2100 Bioanalyzer. Western blotting was performed using monoclonal antibodies and miRNA expression was analyzed in engineered cell lines. Libraries produced were sequenced using the HiSeq 2000 (Illumina; San Diego, CA, USA), producing 100 bp paired-end reads.
Examination of tumor miRNA expression, in vitro processing assays and genomic editing in human cells demonstrated that the gene mutations in endoribonuclease Dicer (DICER1) and ribonuclease 3 (DROSHA) influence miRNA processing through distinct mechanisms.
James F. Amatruda, MD, PhD, a Professor of Pediatrics, Molecular Biology, and Internal Medicine, and senior author of the study said, “The most common, and in some ways the most biologically interesting, mutations were found in genes called DROSHA and DICER1. We found that these mutations affected the cell's production of microRNAs, which are tiny RNA molecules that play big roles in controlling the growth of cells, and the primary effect was on a family of microRNAs called let-7. Let-7 is an important microRNA that slows cell growth and in Wilms tumors in which DROSHA or DICER1 were mutated, let-7 RNA is missing, which causes the cells to grow abnormally fast.” The study was published on September 5, 2014, in the journal Nature Communications.
Related Links:
University of Texas Southwestern Medical Center
Agilent Technologies
Illumina
Read the full article by registering today, it's FREE!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
- Free digital version edition of LabMedica International sent by email on regular basis
- Free print version of LabMedica International magazine (available only outside USA and Canada).
- Free and unlimited access to back issues of LabMedica International in digital format
- Free LabMedica International Newsletter sent every week containing the latest news
- Free breaking news sent via email
- Free access to Events Calendar
- Free access to LinkXpress new product services
- REGISTRATION IS FREE AND EASY!
Sign in: Registered website members
Sign in: Registered magazine subscribers
Latest Molecular Diagnostics News
- Respiratory Panel to Help Clinicians Make Precise Treatment Decisions in Outpatient Settings
- Integrating Cardiovascular Risk Biomarkers Aids in Detection of ‘Inflammaging’
- Genetic Signature in Newborns Predicts Neonatal Sepsis Before Symptoms Appear
- Integrating Multiple Protein Markers Predicts Health Outcomes in Chronic Kidney Disease Patients
- Rapid Finger Prick Blood Test to Detect Active Syphilis at Point of Care
- Urine Tests Could Reveal Early Signs of Cancer and Other Diseases
- AI-Powered Smart PCR System to Revolutionize Clinical Diagnostics
- Simple Blood Test Identifies Women in Labor at Risk for Preeclampsia
- Point-Of-Care Paper-Based Test Could Diagnose Cancer at Bedside
- Sepsis Test Demonstrates Clinical Utility in Critically Ill Heterogeneous Patient Populations
- Multi-Cancer Early Detection Test Measures Host Response to Tumor Development
- MicroRNA-Based Test Identifies 12 Cancers Simultaneously Across Any Stage
- New Blood Test Platform Simultaneously Measures Over 100 Biomarkers of Alzheimer's Disease
- First-Ever Blood Test Diagnoses Maternal Autoantibody Related Autism
- Precision Medicine Blood Test Predicts Heart Disease Before It Occurs
- Blood-Based PCR Test Guides Alzheimer's Therapy